Fisher E R, Anderson S, Redmond C, Fisher B
Headquarters National Surgical Adjuvant Breast Project, Shadyside Hospital, Pennsylvania.
Cancer. 1993 Apr 15;71(8):2507-14. doi: 10.1002/1097-0142(19930415)71:8<2507::aid-cncr2820710813>3.0.co;2-0.
Prognostic pathologic and clinical features for 10-year survival were determined from 22 pathologic and 5 clinical variables encountered in 1090 node-negative and 651 node-positive patients enrolled in NSABP protocol B-06.
All factors were first screened univariately. Those exhibiting P values < 0.01 were entered into multivariate Cox regression models. The model with the best fit consisted of 951 negative-node and 496 node-positive patients.
Better survival in node-negative patients was noted for whites rather than blacks, for patients with favorable tumor types (tubular, mucinous, papillary) rather than intermediate (lobular invasive, classical medullary, and not otherwise specified [NOS] combinations) or unfavorable forms (NOS pure and atypical medullary), and for tumors with good rather than poor nuclear grade. Number of nodal metastases, degree of tumor elastosis, and patient age younger than 40 years of age and 65 years of age and older in addition to nuclear grade and race were found significant for node-positive patients. Relative risks for combinations of these prognostic factors were multiplicative.
The prognostic factors for node-negative patients were similar to those observed for this cohort at 8 years. Some differences noted between patients of both nodal groups in NSABP B-04 and B-06 may be related to selection requirements in the latter and hence different patient characteristics or more speculatively a change in tumor biology.
从参与NSABP B - 06方案的1090例淋巴结阴性和651例淋巴结阳性患者所遇到的22项病理变量和5项临床变量中,确定了10年生存率的预后病理和临床特征。
首先对所有因素进行单因素筛选。将P值<0.01的因素纳入多变量Cox回归模型。拟合度最佳的模型包括951例淋巴结阴性患者和496例淋巴结阳性患者。
淋巴结阴性患者中,白人比黑人的生存率更高;肿瘤类型良好(管状、黏液性、乳头状)的患者比中等类型(小叶浸润性、经典髓样,以及未另行指定[NOS]组合)或不良类型(NOS单纯型和非典型髓样)的患者生存率更高;核分级良好的肿瘤患者比核分级差的患者生存率更高。对于淋巴结阳性患者,除核分级和种族外,淋巴结转移数量、肿瘤弹性变性程度以及年龄小于40岁和65岁及以上的患者也具有显著意义。这些预后因素组合的相对风险具有相乘性。
淋巴结阴性患者的预后因素与该队列8年时观察到的因素相似。NSABP B - 04和B - 06中两组淋巴结患者之间的一些差异可能与后者的选择标准有关,因此患者特征不同,或者更具推测性地与肿瘤生物学变化有关。